Pharmacokinetics and Drug-Drug Interaction of Allisartan Isoproxil and Indapamide Sustained-Release Formulation

Yi, W; Lin, SS; Hao, R; Shao, YM; Wang, YN; Yu, J; Fang, L; Zhu, JJ; Wang, AW; Wu, YF; Huang, H; Deng, CY; Sun, JC; Zhao, HC; Wang, Y; Tong, XM

Tong, XM (通讯作者)，Soochow Univ, Dept Clin Med, Med Coll, Suzhou, Peoples R China.;Tong, XM (通讯作者)，Zhejiang Prov Peoples Hosp, Canc Ctr, Key Lab Tumor Mol Diag & Individualized Med Zhejia, Affiliated Peoples Hosp, Hangzhou, Peoples R China.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023; 12 (11): 1051

Abstract

Allisartan isoproxil (AI) is an angiotensin II type 1 receptor blocker and be converted into the active substance EXP3174 in vivo. We evaluated the dr......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索